{"id":"matching-placebo-to-aliskiren","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1639","moleculeType":"Small molecule","molecularWeight":"551.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, this product contains no active pharmaceutical ingredient and serves as a control comparator in clinical trials. Aliskiren itself works by directly inhibiting renin, the enzyme that initiates the cascade of blood pressure regulation. By blocking renin, it prevents the formation of angiotensin II, thereby reducing vasoconstriction and aldosterone secretion.","oneSentence":"This is a matching placebo formulation designed to mimic Aliskiren, a direct renin inhibitor that blocks the first step of the renin-angiotensin-aldosterone system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:00.063Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in clinical trials of Aliskiren for hypertension"}]},"trialDetails":[{"nctId":"NCT01090310","phase":"PHASE3","title":"Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08","conditions":"Non-infectious Uveitis","enrollment":86},{"nctId":"NCT01922141","phase":"PHASE4","title":"Aliskiren Study of Safety and Efficacy in Senior Hypertensives","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05","conditions":"Hypertension","enrollment":""},{"nctId":"NCT00498433","phase":"PHASE2","title":"Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension","status":"TERMINATED","sponsor":"Novartis","startDate":"2007-06","conditions":"Hypertension, Abdominal Obesity","enrollment":46},{"nctId":"NCT00549757","phase":"PHASE3","title":"Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-10","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":8606},{"nctId":"NCT00894387","phase":"PHASE3","title":"Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-05","conditions":"Acute Decompensated Heart Failure, Congestive Heart Failure","enrollment":1639},{"nctId":"NCT01368536","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":"Hypertension, Stage 2 Hypertension, Diabetes","enrollment":975},{"nctId":"NCT01302899","phase":"PHASE2","title":"To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Non-diabetic Nephropathy","enrollment":8},{"nctId":"NCT01125514","phase":"PHASE2","title":"A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-05","conditions":"Heart Failure","enrollment":37},{"nctId":"NCT00923156","phase":"PHASE2","title":"Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-05","conditions":"Heart Failure","enrollment":123},{"nctId":"NCT00414609","phase":"PHASE3","title":"Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-12","conditions":"Myocardial Infarction","enrollment":820},{"nctId":"NCT01237223","phase":"PHASE3","title":"Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-10","conditions":"Essential Hypertension","enrollment":1342},{"nctId":"NCT01042392","phase":"PHASE4","title":"Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-11","conditions":"Essential Hypertension","enrollment":506},{"nctId":"NCT00768040","phase":"PHASE2","title":"Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-09","conditions":"Diabetic Macular Edema","enrollment":39},{"nctId":"NCT00631917","phase":"PHASE4","title":"A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Hypertension","enrollment":774},{"nctId":"NCT00819767","phase":"PHASE2","title":"Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-02","conditions":"Hypertension","enrollment":68},{"nctId":"NCT00654875","phase":"PHASE4","title":"Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-03","conditions":"Essential Hypertension","enrollment":328}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Matching placebo to Aliskiren","genericName":"Matching placebo to Aliskiren","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a matching placebo formulation designed to mimic Aliskiren, a direct renin inhibitor that blocks the first step of the renin-angiotensin-aldosterone system. Used for Used as control in clinical trials for hypertension management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}